Allergy is a cross-cutting field overlapping broadly with internal medicine, pediatrics, dermatology, and otolaryngology as a declared specialty. Clinics more commonly declare it jointly — "pediatrics and allergy," "internal medicine and allergy," "dermatology and allergy" — than alone.
The demand base is enormous. Cedar pollen allergy alone affects an estimated 30 million people. The domestic hay fever market is estimated at roughly ¥100 billion, with insured care costs at about ¥360 billion and over-the-counter medications about ¥40 billion. Roughly 70% of patients are described as severe or very severe, and work efficiency drops 35–60% at symptom peak — making the social cost through lost productivity (presenteeism) the backdrop to strengthened national measures.
The government established a ministerial council in 2023 with three pillars — source control, expanded preventive treatment, and public understanding — and the Oto-Rhino-Laryngological Society of Japan has set a goal of "zero severe hay fever by 2030." Allergy care sits within a policy tailwind.
1. Macro environment — revenue stability under wage and cost inflation
The FY2026 revision raised base fees 3.09%, weighted toward wage and inflation response, with "data-driven outcome evaluation" and "healthcare DX and cybersecurity" demanded more strongly of clinics.
Points bearing directly on clinic operations include (1) large increases in the base-up evaluation fee (first visit from 6 to about 17 points), (2) a new inflation response item at first and return visits (about 2 points each), (3) restructuring of healthcare DX add-ons (the former promotion readiness add-on consolidated into a new electronic clinical information coordination add-on, with cybersecurity made a requirement), and (4) mandatory blood testing at least every six months under the lifestyle disease management fee.
The direction points to shared challenges: how to absorb personnel and material cost increases, and how to connect digital readiness to billing. For allergy practices, holding a deep book of recurring care — sublingual immunotherapy (SLIT) and biologics — connects directly to revenue stability through wage and cost inflation.
The competitive structure as a declared specialty is maturing. Neighboring otolaryngology peaked at about 5,870 clinics in 2014 and edged down to about 5,681 by 2023, with hay fever demand assessed as "supporting stable patient volume while having settled as a growth driver for new openings." Read the other way, general outpatient care alone no longer differentiates, and clear positioning built on allergy expertise is becoming the winning path for new entrants.
2. Characteristics of newly opened clinics
First, differentiation through specialist credentials and specialized staff. Some clinics foreground physicians holding board certification in both allergy and pediatrics, plus allergy educator nurses. Because educational engagement — lifestyle guidance, medication instruction, environmental adjustment — shapes outcomes in allergy care, team capability including allied health staff differentiates more readily than physician skill alone.
Second, targeting across the pediatric-adult boundary. Allergy care has traditionally fragmented — pediatrics for children, ENT for the nose, dermatology for the skin — but new clinics deliberately accept allergy broadly "from children to adults" and "across nose, skin, and respiratory," capturing continuing visits at the family and life-stage level. Completing the vertical continuity — a child with food allergy growing into an adult with asthma and hay fever — within one clinic is the strength.
Third, revenue design that smooths seasonality. Hay fever is classic seasonal demand concentrated from January to April, and depending on it alone leaves quiet-season capacity idle. The standard design therefore combines year-round conditions (perennial allergic rhinitis, atopic dermatitis, asthma, chronic urticaria) with recurring treatments that can be started year-round (dust mite SLIT, regular biologic dosing, food challenge testing).
Fourth, booking, online delivery, and digital as standard equipment. Because waiting times become a business risk during hay fever peak (patient dropout, reputation damage), web booking and queue systems are near-prerequisites. Hay fever and allergic rhinitis are highly compatible with online consultation, and major platforms have entered both insured and self-pay online hay fever care — making them competitors and, simultaneously, a reason to build the clinic's own online pathway.
Opening capital for the neighboring otolaryngology field is benchmarked at roughly ¥70–90 million including equipment, or about ¥100 million including working capital.
3. Revenue areas specific to allergy
What most distinguishes the revenue structure is holding multiple recurring treatments that generate years of continuing visits once started.
Sublingual immunotherapy (SLIT, cedar and dust mite)
The backbone of allergy practice. Cedarcure for cedar pollen and Miticure for dust mite, both insured, with daily dosing continued over three to five years as standard.
Visits start at two- and four-week intervals, then settle into every four to eight weeks, at roughly ¥2,000–2,500 monthly at 30% coinsurance, with about ¥6,000 for the initial consultation including blood testing.
The business implication is straightforward: SLIT patients accumulate as regular return visits over years once started, so as patient numbers grow, the season-independent revenue base thickens.
Dust mite SLIT can be started year-round, making it important as an off-season entry point. Cedar SLIT, by contrast, generally cannot be started during pollen season, with initiation limited to roughly after the Golden Week holidays in May through year end — so systematically following up hay fever patients seen during the season toward SLIT initiation for the next season is the key to converting demand into revenue. Eligibility generally starts at age six, with pediatric initiation expanding.
Oral food challenge testing
The procedure that most symbolizes pediatric allergy expertise, used for definitive diagnosis of food allergy, confirmation of tolerance acquisition, and clearance decisions. Billed as the pediatric food allergy challenge test (D291-2), the FY2024 values were 1,000 points, under 16 years of age, up to three times in 12 months, requiring facility standard filing and written consent (with a copy attached to the chart). Verify FY2026 values against primary sources.
Performing facilities are published in the Food Allergy Research Group's list. Challenge testing requires emergency response capability, staffing, and time slots, making the entry bar high — but for that reason it becomes a highly specialized patient acquisition mechanism where few nearby facilities can respond, and a core differentiator for pediatric allergy practice.
Biologics for severe allergic disease
Regular outpatient administration of injectables such as dupilumab and omalizumab is expanding rapidly for atopic dermatitis, bronchial asthma, chronic sinusitis, chronic idiopathic urticaria, and severe hay fever.
Dupilumab has been administered to over 150,000 patients in Japan, growing into a mainstay of Sanofi's domestic revenue and expanding into COPD and pediatric asthma (ages 6–11). Omalizumab is used for severe cedar pollen allergy (age 12+, with dosing determined by prior blood testing).
With high drug unit values and administration and management requiring regular visits, biologics are becoming a revenue pillar alongside SLIT — recurring, high-value care for severe patients. But high-cost drugs are also a target of cost containment, so revision developments require continuous monitoring against primary sources.
Seasonal smoothing through year-round conditions
Atopic dermatitis, bronchial asthma, perennial allergic rhinitis, and chronic urticaria complement the hay fever peak and smooth annual utilization. Being able to accept patients across skin, respiratory, and nasal domains is what gives allergy its advantage over single-specialty competitors in ENT, dermatology, and pediatrics.
Viewed as a whole, the winning path converges on one point: entering through the large flow demand of hay fever, then reliably converting it into recurring care — SLIT, biologics, year-round conditions, food challenge testing — to smooth seasonality.
4. Self-pay services
Allergy weights heavily toward insured care, but self-pay touchpoints are expanding.
First, self-pay allergy testing. A 39-item panel from a single blood draw is insured at roughly ¥5,000–6,000 at 30% coinsurance when the physician judges it necessary, but some facilities offer it as self-pay for asymptomatic requests and screening needs. Because it captures pollen, dust mite, and food sensitivities at once, it also functions as pre-treatment screening for SLIT and biologics, creating a natural pathway from testing into specialized treatment.
Second, future diversification in cedar pollen allergy treatment. The government is advancing public-private study of practical application of "cedar pollen rice," with policy support broadening the base of the allergen immunotherapy market itself.
Third, adjacent self-pay menus. Some clinics have introduced high-dose vitamin C infusion and similar constitutional, immune, and aesthetic menus to supplement quiet-season revenue and raise unit value. Dermatology-attached practices commonly pair this with aesthetic dermatology. But raising the self-pay share excessively risks damaging the brand of an allergy practice chosen for expertise, so positioning self-pay as complementary on a foundation of insured-care trust is the realistic design.
5. Management implications
In one sentence: success turns on how reliably seasonal flow demand (hay fever) converts into recurring revenue.
Hay fever is an enormous annual entry point of tens of millions of people, but it is inherently episodic and seasonally concentrated, exposed to waiting times, price competition, and online entrants. Accumulating recurring revenue around three axes is therefore the key to stability through wage and cost inflation:
- Follow-up design that systematically connects hay fever patients to cedar SLIT initiation for the next season, or year-round dust mite SLIT
- Capability to manage severe patients continuously through regular biologic dosing
- Pediatric food challenge testing as a highly specialized acquisition mechanism
On differentiation, team capability including specialists and allergy educators, and targeting across pediatric to adult and nose to skin to respiratory, produce advantage against single-specialty competitors. Web booking and an online consultation pathway are near-mandatory for seasonal smoothing and waiting time management.
Self-pay is best placed cautiously within the range that complements insured care — screening tests, infusion therapy — with a design that does not erode the specialty brand.
6. How an AI EMR addresses these problems — feature by feature
What sustains an allergy practice is not the seasonal hay fever peak but recurring visits for SLIT, biologics, and year-round conditions. Put the other way, one patient discontinuing costs you years of revenue. Here is how Pottech's AI Karte helps you not lose them, feature by feature.
Feature 1: Patient PHR app integration ("Pote-kun") — preventing discontinuation is protecting recurring revenue
Medication reminders, appointment booking, pre-visit web questionnaires, and LINE login with push notifications.
SLIT is daily dosing continued at home over three to five years. Benefit takes time to feel, and patients readily discontinue on their own judgment during symptom-free periods. Biologics likewise presuppose regular dosing.
Discontinuation degrades clinical outcomes and simultaneously destroys years of recurring revenue. Medication reminders and next-visit notifications directly support this specialty's revenue structure.
More important still is the timing of cedar SLIT initiation. It cannot be started during pollen season; initiation opens roughly after the May holidays. Meaning that for hay fever patients seen in February through April, whether you can reach out months later to say "you can start now" determines conversion into revenue. That time-delayed follow-up can rely on neither the patient's memory nor the physician's.
Feature 2: Charting and orders — support high-throughput care at peak
AI generates SOAP notes from consultation audio, web and paper questionnaires are digitized by camera, and set orders enter tests and prescriptions in one action.
Waiting time at hay fever peak is a business risk — patient dropout and reputational damage. Documentation falling behind extends waits directly, so reducing documentation time is waiting time management itself.
At the same time, allergy care is a field where educational engagement — lifestyle guidance, medication instruction, environmental adjustment — shapes outcomes. Redirecting documentation time toward instruction bears on care quality as well.
Feature 3: Billing and claims — secure billing for high-cost drugs and specialized testing
An automated calculation engine checks bundling conflicts, exclusions, and frequency limits, and determines eligibility automatically.
Oral food challenge testing (D291-2) carries frequency limits — under 16 years of age, up to three times in 12 months — plus facility standard filing and written consent requirements. Biologics carry high drug unit values requiring management of dosing intervals and indications.
High-cost drugs are also a cost containment target, making bundling treatment and other revision developments prone to change. Encoding billing logic in the system carries meaning for both avoiding claim reductions and absorbing revisions.
Feature 4: Document generation — reduce the burden of consent and procedure records
AI generates medical documents from patient data, with registered templates preserving the clinic's format.
Food challenge testing requires written consent (with a copy attached to the chart) as a billing requirement, alongside emergency response procedure documentation. Where consent documents and procedure records are heavy, templating and document management serve both requirement compliance and labor efficiency.
Allergy management plans for schools and nurseries are another document demand distinctive to this specialty.
Feature 5: Booking and reception — absorb peak and trough by design
In-person and online bookings are managed together with segmented slot management.
The January-to-April peak concentrates hay fever first and return visits. Simultaneously, continuing patients arrive for SLIT, biologics, and atopic dermatitis. If continuing patients drop out during congestion, years of recurring revenue are lost.
Managing half-day testing slots for food challenges alongside short general outpatient encounters on one calendar is also necessary. Challenge testing requires emergency response capability, limiting the days and times it can be performed.
Feature 6: Practice analytics — measure flow and stock separately
Visit volume, revenue per patient, monthly trends, and patient attributes are aggregated and visualized automatically.
The management challenge here is whether flow demand is converting into recurring care. But watching combined revenue alone does not reveal whether that conversion is happening.
Net growth in SLIT patients, biologic patients on regular dosing, continuing patients with year-round conditions — tracking these monthly as independent metrics is the foundation of judgment not driven by seasonality. The quiet-season revenue mix in particular directly indicates whether the conversion is working.
Primary sources
- MHLW, "About the FY2026 fee schedule revision" https://www.mhlw.go.jp/stf/newpage_67729.html
- Yuyama, "Key points and countermeasures for the FY2026 revision" https://www.yuyama.co.jp/column/medicalrecord/revision-of-medical-fees-2026-2/
- Clinic For, "Sublingual immunotherapy (cedar pollen, dust mite)" https://www.clinicfor.life/disease-tx/allergy/sublingual/
- Knowlety, "Pediatric food allergy challenge test — FY2024 revision (D291-2)" https://knowlety.jp/ika/r6-d291-2/
- Food Allergy Research Group, "List of facilities performing oral food challenge" https://www.foodallergy.jp/ofc/
- Japanese Society of Pediatric Allergy and Clinical Immunology, "On the FY2024 insured care revision" https://www.jspaci.jp/news/member/20240618-4824/
- Medical Plus, "ENT clinic opening trends" https://www.medicalplus.info/trend/department/otorhinolaryngology/
- Power Interactive, "The hay fever market and the zero-severe-cases campaign" https://www.powerweb.co.jp/blog/entry/2024/03/06/100000
- MAFF, "Public-private review committee materials on practical application of cedar pollen rice" https://www.affrc.maff.go.jp/docs/sugikahunnmai/attach/pdf/240123-5.pdf
- Medical Saponet, "Sanofi FY2025 domestic revenue and Dupixent indication expansion" https://medical-saponet.mynavi.jp/news/newstopics/detail_5163/